ASH 2021 | The role of CAR-T therapy in hematologic malignancies
Michael Bishop, MD, University of Chicago, Chicago, IL, describes advances in chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. Data from the JULIET (NCT02445248), TRANSFORM (NCT03575351), BELINDA (NCT03570892), ZUMA-1 (NCT02348216), and ZUMA-7 (NCT03391466) trials have demonstrated CAR T-cell therapy as a promising frontline therapy in non-Hodgkin lymphoma. Dr Bishop additionally highlights updates in multiple myeloma and acute lymphoblastic leukemia (ALL), as well as strategies to manage CAR T-cell toxicity. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
So I had the pleasure and honor of chairing a Friday symposium entitled ‘advances in CAR T-cell therapy across hematologic malignancies. And I was joined by Dr Jesus Berdeja from the Sarah Cannon Cancer Institute in Nashville, and Dr Jae Park from Memorial Sloan Kettering. I spoke in regard to a general overview of CAR T-cell therapies and recent advances in non-Hodgkin’s lymphoma. There’s been a number of updates from prior trials, such as JULIET and ZUMA-1, plus some new, very exciting data on uses of CAR T-cells in upfront therapy, as for non-Hodgkin’s lymphoma, and also an overview of ZUMA-7, TRANSFORM and BELINDA, which will be presented here at the American Society of Hematology...
So I had the pleasure and honor of chairing a Friday symposium entitled ‘advances in CAR T-cell therapy across hematologic malignancies. And I was joined by Dr Jesus Berdeja from the Sarah Cannon Cancer Institute in Nashville, and Dr Jae Park from Memorial Sloan Kettering. I spoke in regard to a general overview of CAR T-cell therapies and recent advances in non-Hodgkin’s lymphoma. There’s been a number of updates from prior trials, such as JULIET and ZUMA-1, plus some new, very exciting data on uses of CAR T-cells in upfront therapy, as for non-Hodgkin’s lymphoma, and also an overview of ZUMA-7, TRANSFORM and BELINDA, which will be presented here at the American Society of Hematology.
Dr Berdeja talked on updates relative to CAR T-cells in multiple myeloma, giving updates on many of the trials, longer term data relative to multiple myeloma, but some of the newer data that was also presented here at ASH. And then Dr Park updated results in acute lymphoblastic leukemia, longer term data, and some of the newer agents that are being investigated, including the use of allogeneic CAR T-cells in acute lymphoblastic leukemia setting, plus looking at management of cytokine release syndrome and neurologic toxicities. And this was a well-received and very enthusiastic session where we know that we’re moving in the right direction and applying CAR T-cells in a broader group of hematologic malignancies.
Read more...
